CHAPTER 25 – A Genomic Approach to the Treatment of Breast Cancer
作者： K.V. CHIN , DEBORAH TOPPMEYER , THOMAS KEARNEY , MICHAEL REISS , EDMUND LATTIME
DOI: 10.1016/B978-012437551-2/50026-4
关键词: Biology 、 Bioinformatics 、 CA15-3 、 Luminal epithelium 、 Doxorubicin 、 After treatment 、 DNA microarray 、 Transcription (biology) 、 Breast cancer 、 Gene
摘要: This chapter discusses a genomic approach to the treatment of breast cancer. Using DNA microarray or proteomic analysis, it should be possible gain an understanding unique susceptibilities individual's cancers. Already, feasibility this analyzing human cancer has been reported, and new concept suggested for origins classification In cancers fell into at least three groups: those luminal cell origin (ER-positive), basal epithelial (ER-negative), HER2/ neu (Erb-2)-positive cells. Each one these was characterized by high expression specific subset genes. Furthermore, recently shown that mutations in BRCA1 BRCA2 can independently influence transcription profile Therefore, sort data viewing all pathways involved ultimate outcome drug-target interaction. way, may select drug is likely effective over not. The work with MCF-7 line which microarrays were done before after doxorubicin, most drugs
sci-hub.st 参考文章(73)
Fred Bunz, Paul M. Hwang, Chris Torrance, Todd Waldman, Yonggang Zhang, Larry Dillehay, Jerry Williams, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Disruption of p53 in human cancer cells alters the responses to therapeutic agents Journal of Clinical Investigation. ,vol. 104, pp. 263- 269 ,(1999) , 10.1172/JCI6863
Graeme I. Murray, Pamela J. Paterson, Richard J. Weaver, Stanley W. B. Ewen, William T. Melvin, M. Danny Burke, The Expression of Cytochrome P-450, Epoxide Hydrolase, and Glutathione S- Transferase in Hepatocellular Carcinoma Cancer. ,vol. 71, pp. 36- 43 ,(1993) , 10.1002/1097-0142(19930101)71:1<36::AID-CNCR2820710107>3.0.CO;2-J
Alan F. Wahl, Karen L. Donaldson, Craig Faircnild, Frank Y.F. Lee, Scott A. Foster, G. William Demers, Denise A. Galloway, Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nature Medicine. ,vol. 2, pp. 72- 79 ,(1996) , 10.1038/NM0196-72
CW Taylor, WS Dalton, PR Parrish, MC Gleason, WT Bellamy, FH Thompson, DJ Roe, JM Trent, Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. British Journal of Cancer. ,vol. 63, pp. 923- 929 ,(1991) , 10.1038/BJC.1991.202
Wolfgang Baumeister, Jochen Walz, Frank Zühl, Erika Seemüller, The Proteasome: Paradigm of a Self-Compartmentalizing Protease Cell. ,vol. 92, pp. 367- 380 ,(1998) , 10.1016/S0092-8674(00)80929-0
R S DiPaola, J Aisner, Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Seminars in Oncology. ,vol. 26, pp. 112- 116 ,(1999)
Ming Tan, Mien Chie Hung, Dihua Yu, Bolin Liu, Shan Shue Wang, Junzhi Li, Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. ,vol. 13, pp. 1359- 1365 ,(1996)
Eric H. Rubin, Tsai-Kun Li, Pu Duann, Leroy F. Liu, Cellular resistance to topoisomerase poisons. Cancer treatment and research. ,vol. 87, pp. 243- 260 ,(1996) , 10.1007/978-1-4613-1267-3_10
Abhijit Raha, Kenneth D. Tew, Glutathione S-transferases. Cancer treatment and research. ,vol. 87, pp. 83- 122 ,(1996) , 10.1007/978-1-4613-1267-3_4
Khew-Voon Chin, Ira Pastan, Michael M. Gottesman, Function and Regulation of the Human Multidrug Resistance Gene Advances in Cancer Research. ,vol. 60, pp. 157- 180 ,(1992) , 10.1016/S0065-230X(08)60825-8